Tuberculosis drug discovery: challenges and new horizons

GFS Fernandes, AM Thompson… - Journal of Medicinal …, 2022 - ACS Publications
Over the past 2000 years, tuberculosis (TB) has claimed more lives than any other infectious
disease. In 2020 alone, TB was responsible for 1.5 million deaths worldwide, comparable to …

Drug-resistant tuberculosis 2020: where we stand

A Iacobino, L Fattorini, F Giannoni - Applied Sciences, 2020 - mdpi.com
Featured Application This comprehensive overview of drug-resistant tuberculosis will be
useful for researchers to expand their knowledge beyond mechanisms other than …

Network pharmacology based virtual screening of active constituents of Prunella vulgaris L. and the molecular mechanism against breast cancer

X Zhang, T Shen, X Zhou, X Tang, R Gao, L Xu… - Scientific reports, 2020 - nature.com
Prunella vulgaris L, a perennial herb widely used in Asia in the treatment of various
diseases including cancer. In vitro studies have demonstrated the therapeutic effect of …

Potential of Marine Terpenoids against SARS-CoV-2: An In Silico Drug Development Approach

A Sahoo, S Fuloria, SS Swain, SK Panda, M Sekar… - Biomedicines, 2021 - mdpi.com
In an emergency, drug repurposing is the best alternative option against newly emerged
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. However, several …

Druggability and drug-likeness concepts in drug design: are biomodelling and predictive tools having their say?

C Agoni, FA Olotu, P Ramharack… - Journal of molecular …, 2020 - Springer
The drug discovery process typically involves target identification and design of suitable
drug molecules against these targets. Despite decades of experimental investigations in the …

Opportunities for Overcoming Mycobacterium tuberculosis Drug Resistance: Emerging Mycobacterial Targets and Host-Directed Therapy

E Torfs, T Piller, P Cos, D Cappoen - International journal of molecular …, 2019 - mdpi.com
The ever-increasing incidence of drug-resistant Mycobacterium tuberculosis infections has
invigorated the focus on the discovery and development of novel treatment options. The …

Mesoporous silica nanoparticles improve oral delivery of antitubercular bicyclic nitroimidazoles

CW Ang, L Tan, Z Qu, NP West… - ACS biomaterials …, 2021 - ACS Publications
Pretomanid and MCC7433, a novel nitroimidazopyrazinone analog, are promising
antitubercular agents that belong to the bicyclic nitroimidazole family. Despite possessing …

DprE1 inhibitors: enduring aspirations for future antituberculosis drug discovery

S Yadav, A Soni, O Tanwar, R Bhadane… - …, 2023 - Wiley Online Library
DprE1 is a crucial enzyme involved in the cell wall synthesis of Mycobacterium tuberculosis
and a promising target for antituberculosis drug development. However, its unique structural …

Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs

L Rodrigues, P Cravo, M Viveiros - Expert review of anti-infective …, 2020 - Taylor & Francis
ABSTRACT Introduction: In 2018, an estimated 377,000 people developed multidrug-
resistant tuberculosis (MDR-TB), urging for new effective treatments. In the last years, it has …

Low-cost anti-mycobacterial drug discovery using engineered E. coli

N Bongaerts, Z Edoo, AA Abukar, X Song… - Nature …, 2022 - nature.com
Whole-cell screening for Mycobacterium tuberculosis (Mtb) inhibitors is complicated by the
pathogen's slow growth and biocontainment requirements. Here we present a synthetic …